Samjin Pharmaceutical Co Ltd
KRX:005500
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Samjin Pharmaceutical Co Ltd
Cost of Revenue
Samjin Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
000100
326030
128940
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
Cost of Revenue
-₩177.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Yuhan Corp
KRX:000100
|
Cost of Revenue
-₩1.3T
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cost of Revenue
-₩34.1B
|
CAGR 3-Years
-158%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cost of Revenue
-₩684.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cost of Revenue
-₩98.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Cost of Revenue
-₩280B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-32%
|
See Also
What is Samjin Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-177.6B
KRW
Based on the financial report for Mar 31, 2024, Samjin Pharmaceutical Co Ltd's Cost of Revenue amounts to -177.6B KRW.
What is Samjin Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%
Over the last year, the Cost of Revenue growth was -9%. The average annual Cost of Revenue growth rates for Samjin Pharmaceutical Co Ltd have been -13% over the past three years , -9% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
